Key facts: DexCom reports $2.8B profit; Wells Fargo cuts price target

robot
Abstract generation in progress

DexCom, Inc. reported a gross profit of $2.8 billion for 2024, a 15% increase from the previous year, despite a dip in gross profit margin due to supply chain issues. As a result, Wells Fargo and Canaccord Genuity have both lowered their price targets for DXCM. DexCom is also expanding its product line with Smart Basal and anticipates increased insurance coverage for type 2 diabetes, which could broaden its market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)